So one big question is whether GLP-1 drugs are adding risk on top of an already elevated baseline, especially in people who are already medically complex
But a growing body of research, and a wave of real-world experience, suggests these drugs may have meaningful benefits for people with T1D too: lower daily insulin doses, flatter glucose curves on your CGM, and potentially better long-term protection for your heart and kidneys
It is therefore in this context, where treatment options for obesity remain very limited, that the appearance of Ozempic and Mounjaro on the market is currently generating enormous interest, both in the medical and scientific communities and in the general population
10% cashback up to 200 on Min Transaction of Rs.1000, for first time users of Airtel Payments Bank
397 BGP-15 stabilizes OPA1, promoting mitochondrial fusion and reducing oxidative stress in HD models